ClinicalTrials.gg
Active, not recruitingNCT06075147Updated Jun 30, 2026

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

An observational study in Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macula Edema (DME), sponsored by Bayer. Active, not recruiting at 18 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Bayer · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Vision Disorders with a site in Australia — 1 open to participants now, 2 under way, 1 of them phase 3. Vision Disorders · Australia.

Started
2024
the only one that year
Observational
Only one
of the 11
Registered
10th of 11
by date
Lead sponsor
3 of 11
Bayer

Among the 11 studies in Vision Disorders with a site in Australia, this one is the only one that started in 2024, is the only observational one, and was the 10th registered.

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

Browse Vision Disorders studies →

Open to participants now

1 of the 11 studies in Vision Disorders with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Vision Disorders with a site in Australia, or all of them as a file.
02

Study summary

This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors.

In this study, data from adults with visual impairment due to neovascular age-related macular degeneration (nAMD) or diabetic macula edema (DME) will be collected and studied.

Visual impairment is any degree of vision loss that affects a person's ability to perform daily activities. nAMD is an eye disorder that causes vision loss due to the growth of abnormal blood vessels that leak blood or retinal fluid into the macula (the central part of the retina). nAMD is a leading cause of vision loss for people aged 50 and older. DME is a diabetes-related eye disorder. In DME, the macula swells up due to fluid leakage from damaged blood vessels, resulting in vision problems.

Aflibercept 8 mg is a drug that is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye.

Aflibercept 8 mg has been submitted for approval for the treatment of visual impairment due to nAMD and DME based on the results from 2 studies called PHOTON and PULSAR. This study will begin once approval is obtained. Currently, no real-world data are available for aflibercept 8 mg.

The main purpose of this study is to collect more information about how well aflibercept 8 mg injection works in people with nAMD and DME. This study will include participants who have not received any prior treatment for nAMD or DME and participants who have.

The main information that researchers will collect:

the change in vision test scores called the best corrected visual acuity (BCVA) after 12 months of treatment.

Data will be collected from February 2024 to September 2027 and will cover a period of up to 24 months per participant. The data will be collected using medical records and by interviewing the patients during regular visits that take place in routine practice.

Researchers will observe participants from the first injection of aflibercept 8 mg until the end of the observation.

In this study, only available data from regular visits will be collected. No visits or tests are required as part of this study.

03

Conditions studied

  • Visual Impairment
  • Neovascular Age-related Macular Degeneration (nAMD)
  • Diabetic Macula Edema (DME)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

SPECTRUM will be performed in eye clinics and ophthalmology practices in several countries across North America, Europe, Middle East, and Asia Pacific.

Female and male patients (aged ≥ 18 years for the DME cohorts or ≥ 50 years for the nAMD cohorts) with a diagnosis of nAMD or DME can be enrolled after the decision for treatment with aflibercept 8 mg has been made by the treating physician. Indications, contraindications, risks, warnings, and precautions according to the local market authorization/local product information should be carefully considered.

For each patient a single eye will be considered as a study eye. The eye treated with aflibercept 8 mg will be considered as study eye. If treatment for both eyes is decided simultaneously, the study eye will be the worse eye as per discretion of the treating physician. Treatment of the 2nd eye will be considered as a concomitant treatment.

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for patients with nAMD

  • A diagnosis of nAMD
  • Patient aged ≥50 years
  • Patients for whom the decision to initiate treatment with intravitreal (IVT) aflibercept 8 mg according to a local product information was made as part of routine clinical practice
  • Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)

Inclusion criteria for patients with DME

  • A diagnosis of DME
  • Patient aged ≥18 years (or country's legal age of adulthood if the legal age is >18 years) with type 1 or type 2 diabetes mellitus
  • Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice
  • Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)

Exclusion Criteria:

Exclusion criteria for all patients with nAMD

  • Participation in an program with interventions outside of clinical routine practice
  • as listed in the local intravitreal aflibercept 8 mg local product information
  • Extra/periocular infection or inflammation in either eye at time of first injection
  • Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
  • Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information Additional exclusion criteria for treatment-naïve patients with nAMD
  • Any prior ocular treatment in the study eye or systemic treatment in nAMD Additional exclusion criteria for pretreated patients with nAMD
  • Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
  • Prior treatment with intravitreal in the study eye within the last 3 months
  • Fluocinolone implant in the study eye within the last 3 years
  • Dexamethasone implant in the study eye within the last 6 months
  • Any concurrent drug releasing implant in the study eye

Exclusion criteria for all patients with DME

  • Participation in an investigational program with interventions outside of clinical routine practice
  • Contraindications as listed in the intravitreal aflibercept 8 mg local product information
  • Extra/periocular infection or inflammation in either eye at time of first injection
  • Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
  • Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information
  • Previous treatment of the study eye with laser in the last 90 days prior to first IVT aflibercept 8 mg Additional exclusion criteria for treatment-naïve patients with DME
  • Any prior ocular treatment in the study eye or systemic treatment in DME Additional exclusion criteria for pretreated patients with DME
  • Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
  • Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months
  • Fluocinolone implant in the study eye within the last 3 years
  • Dexamethasone implant in the study eye within the last 6 months
  • Any concurrent drug releasing implant in the study eye
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • naïve nAMD

    Treatment-naive patients with nAMD

    Drug: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

  • pretreated nAMD

    Pretreated patients with nAMD

    Drug: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

  • naïve DME

    Treatment-naïve patients with DME

    Drug: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

  • pretreated DME

    Pretreated patients with DME

    Drug: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

Interventions

  • DrugAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.

06

What researchers measure

Primary outcomes

  1. The change of best corrected visual acuity (BCVA) from baseline to 12 months as evaluated in routine clinical practice

    BCVA measurements at baseline (first injection of aflibercept 8 mg) and at 12 months as ETDRS letters (according to the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or other methods (e.g. Snellen charts) used in the routine clinical practice in participating countries or sites (with conversion to ETDRS))

    Time frame: At baseline and 12 months

Secondary outcomes

  1. The change of best corrected visual acuity (BCVA) from baseline to 4 weeks, 8 weeks, 6 months, and 24 months as evaluated in routine clinical practice

    Time frame: At baseline, 4 weeks, 8 weeks, 6 months and 24 months

  2. Number of aflibercept 8 mg injections in the study eye during the first 6 months, the first year (12 months), the second year (24 months), and the entire observation period (last visit), respectively

    Performed intravitreal aflibercept 8 mg injections in study eye (including date)

    Time frame: Up to 24 months

  3. Number of visits regarding the study eye by type of visit during the first 6 months, the first 12 months, and the 24 months treatment period

    Performed different type of visits for study eye

    Time frame: Up to 24 months

  4. Number of treated study eyes with 5, 10, and 15 letters (or equivalent) BCVA gain/loss from baseline at 4 weeks, 8 weeks, 6, 12, and 24 months

    Time frame: At baseline, 4 weeks, 8 weeks, 6, 12 and 24 months

  5. Change in central retinal thickness as measured by optical coherence tomography (OCT) from baseline to 4 weeks, 8 weeks, 6, 12, and 24 month follow up

    Time frame: At baseline, 4 weeks, 8 weeks, 6, 12 and 24 months

  6. Number of participants with (serious) adverse events and (serious) drug-related adverse events

    Time frame: From the first application of aflibercept 8 mg up to 24 months

07

Study locations

18 sites
  • Many Locations
    Multiple Locations, Australia
  • Many Locations
    Multiple Locations, Canada
  • Many Locations
    Multiple Locations, Denmark
  • Many Locations
    Multiple Locations, Finland
  • Many Locations
    Multiple Locations, France
  • Many Locations
    Multiple Locations, Germany
  • Many Locations
    Multiple Locations, Italy
  • Many Locations
    Multiple Locations, Japan
  • Many Locations
    Multiple Locations, Netherlands
  • Many Locations
    Multiple Locations, Norway
  • Many Locations
    Multiple Locations, Portugal
  • Many Locations
    Multiple Locations, Saudi Arabia
  • Many Locations
    Multiple Locations, South Korea
  • Many Locations
    Multiple Locations, Spain
  • Many Locations
    Multiple Locations, Sweden
  • Many Locations
    Multiple Locations, Switzerland
  • Many Locations
    Multiple Locations, United Arab Emirates
  • Many Locations
    Multiple Locations, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Sep 2027, 43 months after the start.

Of 58 observational studies under Vision Disorders, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 10, 2023
StartActual
Feb 15, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Jan 31, 2028
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06075147
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Feb 15, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Jun 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion